Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia

Overview

The purpose of the study is to investigate these effects of Second-Generation Antipsychotic (SGAs) on glucose and lipid metabolic parameters in patients with schizophrenia, and explore the relationship between genes polymorphisms (such as drug metabolic enzyme, Endogenous Cannabinoid Receptor Type 1(CB1) and so on) and the SGAs-induced glucose and lipid metabolic disorder in Chinese Han persons with schizophrenia who are taking one of the SGAs(olanzapine, risperidone or ziprasidone).

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 2017

Detailed Description

SGAs now is used as the main tool to treat schizophrenia, however,the mechanism of glucose and lipid metabolism disorder it brings is still unclear. Based on the previous studies, the investigators found that the CB1 gene has a close connection with the metabolism disorder.The investigators suppose that the CB1 also has a significant role in regulation of energy and metabolism in hypothalamus. In this study ,the investigators will recruit 300 Patients with schizophrenia who defined by Diagnostic and Statistical Manual-5 (DSM-5), aged 18 to 60,and all the participants will receive a 6-week systematic treatment by one of the SGAs(including olanzapine, risperidone oral solution, ziprasidone capsules), and a battery of assessments of treatment effect and safety. Plasma concentration will be tested regularly, and these genes polymorphisms of CB1 and other associated with energy metabolism will be conducted by the second generation of gene detection techniques.This study could provide evidence and data to achieve the aim of individualized medication, reduce the drugs' side effect, also throw light on the production of medication for correct the metabolism disorder.

Arms, Groups and Cohorts

  • Olanzapine group
    • Following the baseline assessment, subjects will enter an open treatment group with Olanzapine(Zyprexa) lasting 6 weeks. The subjects will start with a dose of 5-10mg/d , which would be adjusted to as low as 10 mg/d or as high as 20 mg/d, based on clinical response.And drug dose adjustments must be completed within 1 week.
  • Risperidone group
    • Following the baseline assessment, subjects will enter an open treatment group with Risperidone oral solution(Risperdal) lasting 6 weeks. The subjects will start with a dose of 1ml/d , which would be adjusted to as low as 4 ml/d or as high as 6 ml/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 4~6ml/d within 1 week.
  • Ziprasidone group
    • Following the baseline assessment, subjects will enter an open treatment group with Ziprasidone Hydrochloride Capsules(Zeldox) lasting 6 weeks. They started with a dose of 40mg/d , which would be adjusted to as low as 80mg/d or as high as 160/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 80~160mg/d within 10 days.

Clinical Trial Outcome Measures

Primary Measures

  • identification of the effect of some genes polymorphism on the development of glucose and lipid metabolism disorder in patients with schizophrenia who are treated with the SGAs
    • Time Frame: measured at week 2

Secondary Measures

  • identification of the change of the body mass index in patients with schizophrenia who are treated with the SGAs
    • Time Frame: measured at baseline、week 2 and 6
    • the ration of participants who are total remission after treatment
  • identification of the change of the level of Fasting Blood Sugar (FBS), 2 hours post prandial (2HPP) in patients with schizophrenia who are treated with the SGAs
    • Time Frame: measured at baseline、week 2 and 6
  • identification of the change of the level of lipid profile in patients with schizophrenia who are treated with the SGAs
    • Time Frame: measured at baseline、week 2 and 6
  • identification of the change of the level of fasting insulin in patients with schizophrenia who are treated with the SGAs
    • Time Frame: measured at baseline、week 2 and 6

Participating in This Clinical Trial

Inclusion Criteria

  • All cases must be in accordance with the DSM-5 schizophrenia or schizophreniform disorder diagnosis standards – Negative and positive symptom scale(PANSS)score ≥ 60 points;Aged 18 to 60 – Did not participate diet or other body mass reduction projects – Did not have physical illness which affects diet or activities – Did not use any antipsychotic drug within 2 weeks – Subject to consent by the Ethics Committee on clinical trials of drugs,Xijing hospital of The Fourth Military Medical University , all the participants signed a written informed consent Exclusion Criteria:

  • Pregnant or lactating women – Patients with serious body disease, such as epilepsy, liver and kidney impairment, digestive system diseases, etc – Obvious abnormalities on physical and laboratory examination – Body mass index(BMI)≥25.0;Fasting plasma glucose(FPG)≥6.1mmol/L or/and 2-hour postprandial blood glucose(2hPG)≥7.8mmol/L or/and somebody has been diagnosed with diabetes and treatment;Fasting triglycerides≥2.2mmol/L – Suffering from other mental disorders in line with DSM-5 diagnostic criteria

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Xijing Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Huaning Wang, Ph.D, Study Chair, Department of Psychiatry,Xijing hospital,Xi’an,China
    • Zhifu Yang, Ph.D, Study Chair, Department of Pharmacy,Xijing hospital,Xi’an,China

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.